BeneluxA

The Beneluxa Initiative on Pharmaceutical Policy is an initiative involving health services in Belgium, the Netherlands, Luxembourg, Austria and Ireland to deliver sustainable access to innovative medications to people in these smaller countries. It was established in April 2015 by Belgium and the Netherlands. Luxemburg joined in September 2015, Austria in June 2016 and Ireland in June 2018. This covers a population of about 43 million people, and other countries may join in the future. The participants cooperate on health technology assessments,[1] horizon scanning, exchange of strategic information and price/reimbursement negotiations.

BeneluxA
Membership
Establishment
• Established
April 2015
• Luxemburg joins
September 2015
• Austria joins
June 2016
• Ireland joins
June 2018

It has, so far, concentrated on really rare treatments and negotiated a successful deal for nusinersen.

In October 2018 it initiated the International Horizon Scanning Initiative as an international not-for-profit association which any country could join.[2]

A similar alliance was initiated in May 2017, the Valletta Declaration, by Cyprus, Greece, Ireland, Italy, Malta, Portugal, Spain, Romania, Slovenia and Croatia. No information about its activities has been released.[3]

References
  1. "Drugmaker urges HSE to revisit pricing of muscle-wasting disease treatment". Irish Times. 25 February 2019. Retrieved 27 February 2019.
  2. "ate to the party but we brought friends: BeneLuxA's horizon scanning initiative". Pharmaforum. 21 November 2018. Retrieved 27 February 2019.
  3. "Emerging Collaboration in EU Drug Pricing and Reimbursement: A Beneluxa Case Study". Pharmexec. 22 August 2018. Retrieved 27 February 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.